Fig. 1: Clinical utility of genome-wide molecular stratification of patients with esophageal adenocarcinoma (EAC).

In this review, studies on EAC were categorized according to the clinical questions they address, either the stratification’s value for prognostication or impact on therapy selection. Several studies combined therapeutic decisions with prognostic assessment of the patients. Particularly relevant examples of subtyping are highlighted. CIMP: CpG island methylator phenotype.